Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen effective Tax Rate Reconciliation — Federal R&D Tax Credits (%) (%)
Form 10-K Income Taxes Note (XBRL)
Latest, FY2025
3.0%
Period ended Dec 31, 2025
Change on a year earlier
-2.4 pts
5.4% in FY2024
History
11 years
Since FY2015
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Effective Tax Rate Reconciliation — Federal R&D Tax Credits (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.0% | -2.4 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 5.4% | +1.9 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 3.5% | +1.5 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 2.0% | -0.1 pts | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 2.1% | +0.7 pts | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 1.4% | +0.4 pts | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 1.0% | +0.2 pts | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 0.8% | +0.2 pts | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 0.6% | -0.1 pts | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 0.7% | -0.7 pts | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 1.4% | – | Form 10-K (filed 2018-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Effective Tax Rate Reconciliation — Federal R&D Tax Credits (%) (%), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/etr_rd_cred
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.